Eleven Biotherapeutics grants ThromboGenics exclusive rights to undisclosed protein therapeutic for back-of-the-eye diseases developed using Eleven's AMP-Rx protein design technology

Eleven Biotherapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

ThromboGenics N.V.

Belgium / Mid-Cap Biopharma ($1-$50 billion)

$1,488.4m on 05/31/2013 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced